Clinical trials: Delusional Disorder
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
This study will examine whether pretreatment with D-cycloserine before cognitive behavioral therapy can reduce impairments still present in people with stable cases of schizophrenia as well as determine which traits make…
- Trial name
- NCT00742079
- Testing
- D-cycloserine, Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder With Psychotic Features
Study of Pharmacotherapy of Psychotic Depression
This study will determine the effectiveness of combining selective serotonin reuptake inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.
- Trial name
- STOP-PD (NCT00056472)
- Testing
- Olanzapine, Sertraline
- Where
- 4 sites in United States, Canada
- Volunteers
- 259 people
- Sponsor
- Weill Medical College of Cornell University
Schizophrenia, Schizoaffective Disorder
D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
This study is a placebo-controlled 12 week trial of DCS augmentation of once-weekly CBT sessions in 60 schizophrenia subjects with antipsychotic-resistant delusions.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT01981759
- Testing
- D-Cycloserine, Cognitive Behavioral Therapy
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- NYU Langone Health
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia, Schizo Affective Disorder
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
This study aims to provide an evidence-based behavioral intervention to reduce violent behavior for individuals experiencing early psychosis.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05756855
- Testing
- adapted behavioral intervention
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University